A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research

Sara S. Faria, Carlos F. M. Morris, Adriano R. Silva, Micaella P. Fonseca, Patrice Forget, Mariana S. Castro, Wagner Fontes* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The fact that cancer is a leading cause of death all around the world has naturally sparked major efforts in the pursuit of novel and more efficient biomarkers that could better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the battle against this type of disease. Mass spectrometry-based proteomics has proven itself as a robust and logical alternative to the immuno-based methods that once dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches such as the natural gap between shotgun discovery-based methods and clinically applicable results have called for the implementation of more direct, hypothesis-based studies such as those made available through targeted approaches, that might be able to streamline biomarker discovery and validation as a means to increase survivability of affected patients. In fact, the paradigm shifting potential of modern targeted proteomics applied to cancer research can be demonstrated by the large number of advancements and increasing examples of new and more useful biomarkers found during the course of this review in different aspects of cancer research. Out of the many studies dedicated to cancer biomarker discovery, we were able to devise some clear trends, such as the fact that breast cancer is the most common type of tumor studied and that most of the research for any given type of cancer is focused on the discovery diagnostic biomarkers, with the exception of those that rely on samples other than plasma and serum, which are generally aimed toward prognostic markers. Interestingly, the most common type of targeted approach is based on stable isotope dilution-selected reaction monitoring protocols for quantification of the target molecules. Overall, this reinforces that notion that targeted proteomics has already started to fulfill its role as a groundbreaking strategy that may enable researchers to catapult the number of viable, effective, and validated biomarkers in cancer clinical practice.
Original languageEnglish
Article number13
Number of pages28
JournalFrontiers in Oncology
Volume7
DOIs
Publication statusPublished - 20 Feb 2017

Fingerprint

Firearms
Proteomics
Biomarkers
Research
Neoplasms
Tumor Biomarkers
Isotopes
Cause of Death
Mass Spectrometry
Research Personnel
Breast Neoplasms
Serum

Keywords

  • targeted proteomics
  • cancer
  • biomarkers
  • mass spectrometry
  • diagnosis

Cite this

A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research. / Faria, Sara S.; Morris, Carlos F. M.; Silva, Adriano R.; Fonseca, Micaella P.; Forget, Patrice; Castro, Mariana S.; Fontes, Wagner (Corresponding Author).

In: Frontiers in Oncology, Vol. 7, 13, 20.02.2017.

Research output: Contribution to journalArticle

Faria, Sara S. ; Morris, Carlos F. M. ; Silva, Adriano R. ; Fonseca, Micaella P. ; Forget, Patrice ; Castro, Mariana S. ; Fontes, Wagner. / A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research. In: Frontiers in Oncology. 2017 ; Vol. 7.
@article{944f67e4bf16438f916cc12aec0da9f3,
title = "A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research",
abstract = "The fact that cancer is a leading cause of death all around the world has naturally sparked major efforts in the pursuit of novel and more efficient biomarkers that could better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the battle against this type of disease. Mass spectrometry-based proteomics has proven itself as a robust and logical alternative to the immuno-based methods that once dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches such as the natural gap between shotgun discovery-based methods and clinically applicable results have called for the implementation of more direct, hypothesis-based studies such as those made available through targeted approaches, that might be able to streamline biomarker discovery and validation as a means to increase survivability of affected patients. In fact, the paradigm shifting potential of modern targeted proteomics applied to cancer research can be demonstrated by the large number of advancements and increasing examples of new and more useful biomarkers found during the course of this review in different aspects of cancer research. Out of the many studies dedicated to cancer biomarker discovery, we were able to devise some clear trends, such as the fact that breast cancer is the most common type of tumor studied and that most of the research for any given type of cancer is focused on the discovery diagnostic biomarkers, with the exception of those that rely on samples other than plasma and serum, which are generally aimed toward prognostic markers. Interestingly, the most common type of targeted approach is based on stable isotope dilution-selected reaction monitoring protocols for quantification of the target molecules. Overall, this reinforces that notion that targeted proteomics has already started to fulfill its role as a groundbreaking strategy that may enable researchers to catapult the number of viable, effective, and validated biomarkers in cancer clinical practice.",
keywords = "targeted proteomics, cancer, biomarkers, mass spectrometry, diagnosis",
author = "Faria, {Sara S.} and Morris, {Carlos F. M.} and Silva, {Adriano R.} and Fonseca, {Micaella P.} and Patrice Forget and Castro, {Mariana S.} and Wagner Fontes",
note = "Funding The present work was funded by FUB/UnB, CNPq, FAP-DF, CAPES, and FINEP.",
year = "2017",
month = "2",
day = "20",
doi = "10.3389/fonc.2017.00013",
language = "English",
volume = "7",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - A Timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research

AU - Faria, Sara S.

AU - Morris, Carlos F. M.

AU - Silva, Adriano R.

AU - Fonseca, Micaella P.

AU - Forget, Patrice

AU - Castro, Mariana S.

AU - Fontes, Wagner

N1 - Funding The present work was funded by FUB/UnB, CNPq, FAP-DF, CAPES, and FINEP.

PY - 2017/2/20

Y1 - 2017/2/20

N2 - The fact that cancer is a leading cause of death all around the world has naturally sparked major efforts in the pursuit of novel and more efficient biomarkers that could better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the battle against this type of disease. Mass spectrometry-based proteomics has proven itself as a robust and logical alternative to the immuno-based methods that once dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches such as the natural gap between shotgun discovery-based methods and clinically applicable results have called for the implementation of more direct, hypothesis-based studies such as those made available through targeted approaches, that might be able to streamline biomarker discovery and validation as a means to increase survivability of affected patients. In fact, the paradigm shifting potential of modern targeted proteomics applied to cancer research can be demonstrated by the large number of advancements and increasing examples of new and more useful biomarkers found during the course of this review in different aspects of cancer research. Out of the many studies dedicated to cancer biomarker discovery, we were able to devise some clear trends, such as the fact that breast cancer is the most common type of tumor studied and that most of the research for any given type of cancer is focused on the discovery diagnostic biomarkers, with the exception of those that rely on samples other than plasma and serum, which are generally aimed toward prognostic markers. Interestingly, the most common type of targeted approach is based on stable isotope dilution-selected reaction monitoring protocols for quantification of the target molecules. Overall, this reinforces that notion that targeted proteomics has already started to fulfill its role as a groundbreaking strategy that may enable researchers to catapult the number of viable, effective, and validated biomarkers in cancer clinical practice.

AB - The fact that cancer is a leading cause of death all around the world has naturally sparked major efforts in the pursuit of novel and more efficient biomarkers that could better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the battle against this type of disease. Mass spectrometry-based proteomics has proven itself as a robust and logical alternative to the immuno-based methods that once dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches such as the natural gap between shotgun discovery-based methods and clinically applicable results have called for the implementation of more direct, hypothesis-based studies such as those made available through targeted approaches, that might be able to streamline biomarker discovery and validation as a means to increase survivability of affected patients. In fact, the paradigm shifting potential of modern targeted proteomics applied to cancer research can be demonstrated by the large number of advancements and increasing examples of new and more useful biomarkers found during the course of this review in different aspects of cancer research. Out of the many studies dedicated to cancer biomarker discovery, we were able to devise some clear trends, such as the fact that breast cancer is the most common type of tumor studied and that most of the research for any given type of cancer is focused on the discovery diagnostic biomarkers, with the exception of those that rely on samples other than plasma and serum, which are generally aimed toward prognostic markers. Interestingly, the most common type of targeted approach is based on stable isotope dilution-selected reaction monitoring protocols for quantification of the target molecules. Overall, this reinforces that notion that targeted proteomics has already started to fulfill its role as a groundbreaking strategy that may enable researchers to catapult the number of viable, effective, and validated biomarkers in cancer clinical practice.

KW - targeted proteomics

KW - cancer

KW - biomarkers

KW - mass spectrometry

KW - diagnosis

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85014631062&partnerID=MN8TOARS

U2 - 10.3389/fonc.2017.00013

DO - 10.3389/fonc.2017.00013

M3 - Article

VL - 7

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 13

ER -